Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 1;37(6):494-505.
doi: 10.1097/QCO.0000000000001067. Epub 2024 Oct 3.

Prenatal and postnatal antiviral therapies for the prevention and treatment of congenital cytomegalovirus infections

Affiliations
Review

Prenatal and postnatal antiviral therapies for the prevention and treatment of congenital cytomegalovirus infections

Preethi Chandrasekaran et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: Congenital cytomegalovirus infection (cCMV) is the leading infectious cause of sensorineural hearing loss and lifelong neurodevelopmental disabilities. Studies suggest antiviral therapy can prevent fetal infection after maternal primary infection, as well as halt the progression of hearing loss and neurodevelopmental disabilities in newborns with symptomatic cCMV. With growing worldwide momentum on early detection and diagnosis of cCMV, this review describes the exciting recent advances in antiviral therapies in CMV infected pregnant mothers and babies, as well as emerging evidence on anti-CMV vaccines.

Recent findings: New opportunities for prenatal and neonatal interventions have driven a rising interest in screening and identification of asymptomatic CMV infection. Routine screening of pregnant women to identify primary infection in first trimester is now advocated in Western Europe but has yet to be examined from a public health perspective in other regions. Evidence is emerging for maternal valaciclovir therapy to prevent fetal infection after a maternal primary CMV infection in the first trimester of pregnancy. For those infants who are born with symptomatic cCMV, a 6-month course of valganciclovir, started within the first 4 weeks of life, and possibly up to 13 weeks of life, is the current recommended therapy. However, there is unclear evidence for the benefit of treatment for asymptomatic cCMV and cCMV with isolated hearing loss. Research to identify more effective antivirals and an effective CMV vaccine continues.

Summary: More research is needed to determine the region-specific applicability of the new European recommendations for routine CMV screening in pregnancy. Areas of uncertainty in postnatal management include timing of initiation, duration of treatment and identifying pediatric subgroups that benefit from modification of the standard treatment recommendations.

PubMed Disclaimer

References

    1. Manicklal S, Emery VC, Lazzarotto T, et al. The “Silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013; 26:86–102.
    1. Nigro G, Anceschi MM, Cosmi EV. Group TCCDC. Page 576 T names of collaborators may be found on. Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. BJOG Int J Obstet Gynaecol 2003; 110:572–577.
    1. Brosh-Nissimov T, Benshalom-Tirosh N, Bucris E, et al. Recurrent congenital cytomegalovirus infection in a sequential pregnancy with severe sequelae, and a possible association with prophylactic valacyclovir treatment: a case report. Int J Infect Dis 2022; 125:93–95.
    1. Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001; 344:1366–1371.
    1. Ssentongo P, Hehnly C, Birungi P, et al. Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis. JAMA Netw Open 2021; 4:e2120736.

MeSH terms

Substances